Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
10% Hemohes · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| 10% Hemohes® (10% Hydroxyethyl starch) | DRUG | - |
| Sterofundin® (Ringer lactate solution) | DRUG | - |
| Actrapid® (Insulin) | DRUG | - |
Inclusion Criteria: * Patients fulfilling the criteria of "severe sepsis" or "septic shock" according to the Society of Critical Care Medicine/American College of Chest Physicians (SCCM/ACCP) definitions not longer than 24 hours before ICU admission or 12 hours after ICU admission Exclusion Criter...
10% Hemohes is an investigational small molecule being studied for the treatment of severe sepsis. It is a volume substitute evaluated in the VISEP trial, which enrolled 600 patients with severe sepsis or septic shock. The drug is still in clinical development and has not been approved.
10% Hemohes is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the stock exchange under the ticker NVO. The company is conducting clinical research on this drug for severe sepsis.
10% Hemohes is in Phase 3 clinical development. It has completed one Phase 3 trial, the VISEP trial, which enrolled 600 patients. The drug remains investigational and is not yet approved for any use.
10% Hemohes has been studied in one completed Phase 3 trial, NCT00135473, titled "Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)." This trial enrolled 600 patients with severe sepsis or septic shock in Germany.
10% Hemohes is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for severe sepsis. The completed VISEP trial did not lead to approval, and the drug remains under study.